Share your research at the 2026 Spring Scientific, Next-generation Cellular Therapies, T cell Engagers, and Combinations. Submissions close on Jan. 15, 2026. Don’t miss the opportunity to submit your Abstract. Learn more: https://sitcancer.org/edu/2026-spring-scientific

New Journal for ImmunoTherapy of Cancer article: In situ DC-primed vaccine combined with CD137 agonist elicits long-lasting antitumor immunity through cDC1-mediated tumor antigen-specific CD8+ T cell responses t.co/MH5lQvHMLw 🧪

#JITC #MedSky #ImmunoSky

This holiday season, the SITC family celebrates you. As we turn the page on a year of uncertainty, we thank the cancer immunotherapy professionals whose tireless work continues to bring hope, advance science, and transform lives. #Immunotherapy #sitc-timeline-timeline" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link" target="_blank" rel="noopener" data-link="bsky">https://www.sitcancer.org/about/mission#sitc-timeline

We are proud to support global scientific exchange! Join leading scientists at the 18th #Breast Gynecological International #Cancer Conference Jan. 22-23 in Cairo, Egypt. View cutting-edge presentations advancing breast and #gynecologic cancer #research. Learn more: https://ow.ly/nAEU50XLtUH

Early registration for our Winter School Program closes tomorrow. Register to understand the fundamentals of how the immune system enables #cancer #immunotherapy. Held in Boston, MA or virtually: sitcancer.org/edu/winterschool

In the December #JITC Digest, Editor-in-Chief Dr. Michael Lotze highlights the latest developments and emerging trends in cancer immunotherapy. This month's selection of manuscripts features a fundamental focus on mechanisms of IO involving Tregs. Read the Dec. Issue: https://ow.ly/mwub50XL4o4

SITC is proud to support OVAC & today’s Day of Action. Together, we can drive progress in cancer research, prevention, and care. We urge Congress to prioritize increased federal funding for #CancerResearch & #CancerPrevention programs.

Cancer remains the nation’s #2 killer—that’s why Society for Immunotherapy of Cancer joins OVAC & fellow members in urging Congress to make vital investments in #CancerResearch & #CancerPrevention:

$47.2B for the NIH
$7.374B for the NCI
$1.5B for ARPA_H
$417.5M for the CDC
#FY26

Today, Society for Immunotherapy of Cancer joins One Voice Against Cancer's (OVAC) Day of Action, urging Congress to pass a full-year funding bill & prioritize funding for the NCI, NIH & CDC for #FY26! We can’t afford to pause progress on cancer research & prevention funding. #CancerVoice25

New Journal for ImmoTherapy of Cancer article: Colorectal cancer organoids drive hypoxia, TGF-β, and patient-specific diversification of NK cell activation programs t.co/QTd6A59Ul5

#JITC #ImmunoSky

Call for Comment: SITC invites public review of the new draft clinical practice guideline on immunotherapy for the treatment of multiple myeloma v2.0. Deadline to submit a request is December 22nd. More at: https://ow.ly/BYii50XIBcP
#MultipleMyeloma #Cancer #SITCGuidelines

Now is the time to receive MOC Credits before the end of the year! Earn the SITC Certificate in #Cancer #Immunotherapy to support your knowledge and skills to provide effective and safe care for patients treated with cancer immunotherapy. Register at: https://www.sitcancer.org/certificate

Jean-Philippe Spano presents, "Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC)” at #ESMOImmuno25.

As Fangling Ning presents data on SIRpα-fc fusion protein at #ESMOImmuno25, address blockade of CD47 with this recent #JITC article from Chilam Chan et al of UMC Utrecht: https://ow.ly/lbJV50XH7A5

#ICYMI: At #ESMOImmuno25, Antonia Busse presented, “A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors”.

At #ESMOImmuno25, Hans Nijman reports how “Neoadjuvant immune checkpoint inhibition skews the B cell response in mismatch repair deficient endometrial cancer”.

As Dimitrios A. Garyfallos shares new findings on, “In vivo CRISPR/Cas9 genetic screens identify novel immunotherapy target” at #ESMOImmuno25, discover more on CRISPR with #JITC!

Exciting science unfolding at #ESMOImmuno25! Today’s oral abstract session featured Andreas Pircher’s presentation on, “Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME)."

Calling IO researchers with interests in cellular therapy, T cell engagers, and immuno-oncology drug development. The 2026 Spring Scientific is the program for you. Early registration rates end Jan. 9, 2026. Register here: https://sitcancer.org/edu/2026-spring-scientific

While at #ASH25, visit SITC in booth 2014 and learn how a membership provides exclusive tools, education and leadership opportunities to progress your career. #SITC #Immunotherapy

Register today to attend the #SITC Winter School Program! This hybrid program provides the best in cancer immunotherapy education taught by leading experts in the field. Held Feb. 16-18, 2026, in Boston, MA, or virtually. sitcancer.org/edu/winterschool

Are you at #ASH25? Visit SITC booth 2014 to learn more about an upcoming free Dec. 17 webinar, Bispecifics and T cell Engagers: Practical Strategies for Recognizing and Managing Toxicities.

Heading to #ASH25? Don’t miss your chance to visit SITC at booth 2014! Learn how SITC’s Advances in Cancer Immunotherapy™ program can help you stay at the forefront of immunotherapy education whether you’re new to the field or looking to deepen your expertise.

Working in Cancer IO? Visit SITC at #ASH25 booth 2014 and learn about the only member-driven society dedicated to cancer immunotherapy research and application. Find out about: ACIs, Cancer Immunotherapy Winter School, JITC, the Spring Scientific, and more!

New Journal for ImmunoTherapy of Cancer article: Neutrophil extracellular traps–STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer jitc.bmj.com/content/13/1...

#JITC #MedSky